ATHENEXPAR Stock

ATNX

US04685N2027

OTC Markets Traded

Analysts' recommendations: ATHENEXPAR

21/03/23	Ladenburg Thalmann Downgrades Athenex to Neutral From Buy	MT
13/04/22	Truist Securities Adjusts Athenex's Price Target to $3 from $6, Keeps Hold Rating	MT
17/03/22	SVB Leerink Adjusts Athenex's Price Target to $3 from $2, Keeps Market Perform Rating	MT
17/03/22	RBC Capital Adjusts Price Target on Athenex to $4 From $5, Maintains Outperform Rating, Assigns Speculative Risk Qualifier	MT
12/10/21	ATHENEX : RBC Cuts Price Target on Athenex to $5 From $8 Amid Discontinuation of Oraxol in Metastatic Breast Cancer; Outperform Kept	MT

More recommendations

Managers and Directors: ATHENEXPAR

Manager	Title	Age	Since
Yiu Nam Lau CEO	Chief Executive Officer	65	01/01/2011
Jacqueline Li PRN	Corporate Officer/Principal	-	01/01/2017
Nick Campbell PRN	Corporate Officer/Principal	47	19/04/2023

Director	Title	Age	Since
Yiu Nam Lau CHM	Chairman	65	01/11/2003
Jinn Wu BRD	Director/Board Member	77	01/04/2007
Manson Fok BRD	Director/Board Member	69	01/06/2015

More insiders

Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Employees

275

Sector

More about the company

22/09/23	Athenex, Inc. Went Out of Business	CI
18/09/23	First Motion for Exclusivity Period Extension Approved For Athenex, Inc.	CI
12/09/23	Liquidation Plan Approved for Athenex, Inc.	CI
08/09/23	First Motion for Exclusivity Period Extension Filed by Athenex, Inc.	CI
18/08/23	Athenex, Inc. Announces the Separation of Joe Annoni as Chief Financial Officer	CI
18/08/23	Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer	CI
10/08/23	Illumina cuts annual profit forecast as biotech funding woes linger	RE
10/08/23	Illumina cuts annual profit forecast	RE
01/08/23	Modified Disclosure Statement Approved on Interim Basis for Athenex, Inc.	CI
01/08/23	Motion for Asset Sale Approved for Athenex, Inc.	CI
26/07/23	Combined Liquidation Plan and Disclosure Statement Filed by Athenex, Inc.	CI
25/07/23	Danaher cuts forecast for annual sales growth as biotech clients face funding crunch	RE
27/06/23	Motion for Asset Sale Approved for Athenex, Inc.	CI

23/05/23	ATHENEX, INC. : Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/05/23	Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process	AQ
04/05/23	ATHENEX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
26/04/23	ATHENEX, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
01/04/23	ATHENEX, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
05/05/23	Timothy Devere Cook	Free	See Remarks	368	0.0042%
05/05/23	Rudolf Kwan	Free	EVP, Chief Medical Officer	3,603	0.0416%
05/05/23	Yiu Nam Lau	Free	Chief Executive Officer	8,382	0.0968%

ATHENEXPAR Stock

Stocks

ATNX

US04685N2027

Latest news : ATHENEXPAR

Analysts' recommendations: ATHENEXPAR

Press Releases: ATHENEXPAR

Managers and Directors: ATHENEXPAR

Latest insider transactions

Company Profile